Evidence map›Paper›PMID 18001769›Full record

ArticleJournal of molecular biology2008

Structural basis for catalysis by onconase.

J Eugene Lee, Euiyoung Bae, Craig A Bingman, George N Phillips, Ronald T Raines

Open access · greenAbstract readComparative Study
In one paragraph

Article in Journal of molecular biology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Ribonucleases as potential modalities in anticancer therapy.European journal of pharmacology · 2009
    Review
  9. Article
  10. Interaction of onconase with the human ribonuclease inhibitor protein.Biochemical and biophysical research communications · 2008
    Article
  11. Article
  12. Review
  13. Review
  14. Ribonucleases as novel chemotherapeutics : the ranpirnase example.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2008
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

J Eugene LeeDepartment of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706-1544, USA.
Euiyoung Bae
Craig A Bingman
George N Phillips
Ronald T Raines
University of Wisconsin–Madison · US

Funding

Center for Eukaryotic Structural GenomicsP50GM064598 · NIGMS · UNIVERSITY OF WISCONSIN MADISON · PI MARKLEY, JOHN L · 2001 to 2004
$23.7M
Specialized Center for Eukaryotic Structural GenomicsU54GM074901 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI MARKLEY, JOHN LUTE · 2005 to 2009
$18.9M
RIBONUCLEASES IN CANCER THERAPYR01CA073808 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI RAINES, RONALD T · 1997 to 2024
$7.3M
NCI NIH HHS CA73808NCI NIH HHS R01 CA073808NIGMS NIH HHS P50 GM064598NIGMS NIH HHS U54 GM074901
6 · The paper itself

Abstract

Onconase (ONC) is a homolog of bovine pancreatic ribonuclease (RNase A) from the frog Rana pipiens. ONC displays antitumoral activity and is in advanced clinical trials for the treatment of cancer. Here, we report the first atomic structures of ONC-nucleic acid complexes: a T89N/E91A ONC-5'-AMP complex at 1.65 A resolution and a wild-type ONC-d(AUGA) complex at 1.90 A resolution. The latter structure and site-directed mutagenesis were used to reveal the atomic basis for substrate recognition and turnover by ONC. The residues in ONC that are proximal to the scissile phosphodiester bond (His10, Lys31, and His97) and uracil nucleobase (Thr35, Asp67, and Phe98) are conserved from RNase A and serve to generate a similar bell-shaped pH versus k(cat)/K(M) profile for RNA cleavage. Glu91 of ONC forms two hydrogen bonds with the guanine nucleobase in d(AUGA), and Thr89 is in close proximity to that nucleobase. Installing a neutral or cationic residue at position 91 or an asparagine residue at position 89 virtually eliminated the 10(2)-fold guanine:adenine preference of ONC. A variant that combined such substitutions, T89N/E91A ONC, actually preferred adenine over guanine. In contrast, installing an arginine residue at position 91 increased the guanine preference and afforded an ONC variant with the highest known k(cat)/K(M) value. These data indicate that ONC discriminates between guanine and adenine by using Coulombic interactions and a network of hydrogen bonds. The structure of the ONC-d(AUGA) complex was also used to probe other aspects of catalysis. For example, the T5R substitution, designed to create a favorable Coulombic interaction between ONC and a phosphoryl group in RNA, increased ribonucleolytic activity by twofold. No variant, however, was more toxic to human cancer cells than wild-type ONC. Together, these findings provide a cynosure for understanding catalysis of RNA cleavage in a system of high medicinal relevance.

Indexed as

Adenosine MonophosphateAlanineAmino Acid SequenceAmino Acid SubstitutionAsparagineBinding SitesCatalysisCrystallography, X-RayDisulfidesGlutamic AcidHumansHydrogen BondingHydrogen-Ion ConcentrationK562 CellsKineticsLysineAdenosine MonophosphateAlanineAsparagineDisulfidesGlutamic AcidLysineProtein Synthesis InhibitorsranpirnaseRibonucleases

Identifiers

PMID18001769
PMCPMC2151974
OpenAlexW2023717652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.